DR. ANIS AHMAD, M.D., F.R.C.P.
Osteopathic Medicine at 7 St, Moline, IL

License number
Illinois 036049910
Category
Osteopathic Medicine
Type
Internal Medicine
Address
Address
3061 7Th St STE A, Moline, IL 61265
Phone
(309) 762-6161
(309) 762-5387 (Fax)

Organization information

See more information about ANIS AHMAD at bizstanding.com

Anis Ahmad MD

3061 7 St #A, Moline, IL 61265

Categories:
Internal Medicine Physicians & Surgeons, Physicians & Surgeons
Phone:
(309) 762-6161 (Phone)
Specialties:
Cardiology, Internal Medicine
Products:
Internal Medicine
Payment options:
American Express, Visa
Additional:
M.D., F.R.C.P.

Professional information

Anis Ahmad Photo 1

Dr. Anis Ahmad, Moline IL - MD (Doctor of Medicine)

Specialties:
Internal Medicine
Address:
Anis Ahmad MD
3061 7Th St STE A, Moline 61265
(309) 762-6161 (Phone)
Languages:
English, Spanish
Hospitals:
Anis Ahmad MD
3061 7Th St STE A, Moline 61265
Allen Memorial Hospital
1825 Logan Ave, Waterloo 50703
Genesis Medical Center – Silvis
801 Illini Dr, Silvis 61282
Genesis Medical Center West - Davenport
1227 East Rusholme St, Davenport 52803
Iowa Lutheran Hospital
700 East University Ave, Des Moines 50316
Saint Lukes Hospital
1026 A Ave North #East, Cedar Rapids 52402
Trinity Medical Center - East
501 10Th Avenue Ct, Moline 61265
Trinity Rock Island
2701 17Th St, Rock Island 61201
Education:
Medical School
King George's Medical College


Anis Ahmad Photo 2

Anis Ahmad, Moline IL

Specialties:
Internist
Address:
3061 7Th St, Moline, IL 61265


Anis Ahmad Photo 3

Use Of Carvedilol For Treatment Of Diabetes Mellitus

US Patent:
8492426, Jul 23, 2013
Filed:
Jul 12, 2012
Appl. No.:
13/547047
Inventors:
Anis Ahmad - Moline IL, US
International Classification:
A61K 31/40
US Classification:
514411
Abstract:
A method of treating diabetes by administering Carvedilol in patients and diabetes mellitus. This method of treatment will eliminate the need for insulin and other blood sugar controlling agents in hypertensive patients with Type II diabetes mellitus, and will significantly reduce the required dosage of insulin and eliminate the need for other blood controlling agents in patients with Type I diabetes mellitus. This method will also delay and/or prevent the progression of non-insulin dependent Type II diabetes mellitus to insulin-dependent Type II diabetes mellitus. Moreover, this method has been shown to preserve improve insulin receptor sensitivity such that patient's HbAlevel reaches and is maintained at or near 7% or less.